On September 19, 2023, DocGo Inc., a prominent provider of mobile health services and integrated medical mobility solutions, received an optimistic affirmation from BTIG. Despite lowering its price target from $15.00 to $13.00, BTIG maintained its Buy rating for DocGo.
Interestingly, as of the aforementioned date, DocGo’s shares experienced a modest increase of 0.28% in the last 24 hours, valuing each share at $5.30. If the stock price were to reach the newly adjusted target of $13.00, it would signify an impressive surge of 145.05% from the current price.
MarketBeat, a reputable source, reveals that DocGo holds an average rating score of 3.00. This score is based on 2 buy ratings, with no hold or sell ratings. The consensus price target of $12.50 suggests a projected upside of 32.6% from the current price of $9.43.
In conclusion, DocGo Inc. continues to garner positive attention and support from BTIG, despite the adjustment in price target. With potential growth on the horizon and a favorable average rating score, the company remains an intriguing prospect for investors.
Updated on: 19/09/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
DCGO Stock Performance: Stable Trading Day on September 19, 2023 with Positive Outlook for Future Earnings Growth
DCGO Stock Performance on September 19, 2023
DCGO, a healthcare services company, had a relatively stable trading day on September 19, 2023. The stock opened at the previous day’s closing price of $5.29 and fluctuated within a range of $5.23 to $5.48 throughout the day. The trading volume was relatively low at 64,194 shares, compared to the average volume of 853,091 shares over the past three months.
With a market capitalization of $591.6 million, DCGO is considered a small-cap stock. Despite its relatively small size, the company has shown positive earnings growth in the past year, with a growth rate of 15.52%. However, this year’s earnings growth has experienced a decline of 33.56%. Looking ahead, analysts expect DCGO to achieve a steady earnings growth rate of 11.39% over the next five years.
The company’s revenue growth in the previous year was impressive, with a growth rate of 38.21%. This indicates that DCGO has been successful in increasing its top-line performance. However, it is important to note that the company’s profitability has been relatively modest, with a net profit margin of 7.85%.
The stock’s valuation metrics also provide some insights into DCGO’s financial performance. With a price-to-earnings (P/E) ratio of 89.1, the stock appears to be relatively expensive compared to its earnings. The price-to-sales ratio of 1.65 and price-to-book ratio of 2.14 suggest that the stock is trading at a moderate valuation in relation to its sales and book value.
It is worth mentioning that no competitor data is available for DCGO, which makes it difficult to assess its performance within the industry. However, the company operates in the health services sector, specifically in the medical/nursing services industry.
Looking ahead, investors can expect the next financial report from DCGO to be released on November 15, 2023. Analysts forecast an earnings per share (EPS) of $0.08 for the current quarter. In terms of annual financials, DCGO reported a revenue of $440.5 million and a profit of $34.6 million in the previous year.
In conclusion, DCGO had a relatively stable trading day on September 19, 2023, with the stock fluctuating within a narrow range. The company has shown positive earnings and revenue growth in the past, although this year’s earnings growth has declined. With a moderate valuation and a positive outlook for future earnings growth, DCGO may present an interesting investment opportunity in the healthcare services sector.
DCGO Stock Shows Positive Performance with Bullish Outlook and Consensus Buy Rating
DCGO stock had a positive performance on September 19, 2023, based on the information provided. According to data from CNN Money, there are 7 analysts offering 12-month price forecasts for DocGo Inc, with a median target of $13.00. The high estimate is $16.00, while the low estimate is $12.00. The median estimate of $13.00 represents a significant increase of 143.22% from the last price of $5.35. This indicates that the analysts have a bullish outlook on DCGO stock and expect it to perform well in the coming months.
Furthermore, the current consensus among the 7 polled investment analysts is to buy stock in DocGo Inc. This rating has held steady since August, indicating that the analysts’ sentiment towards the stock has remained positive and unchanged.
In terms of financial performance, DocGo Inc reported earnings per share of $0.08 for the current quarter. Additionally, the company reported sales of $131.4 million. These figures suggest that the company is performing well financially, which may contribute to the positive outlook from analysts.
Investors can expect more information about DocGo Inc’s financial performance on November 15, as that is the reporting date for the current quarter.
Overall, based on the analysts’ price forecasts, consensus buy rating, and the company’s financial performance, DCGO stock appears to have a positive outlook for September 19, 2023.